PHYSIOLOGIC GH ADMIN ON CARDIOVASCULAR RISK MARKERS IN WOMEN WITH GH DEFICIENCY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular mortality in growth hormone (GH) deficient adults has been shown to be increased in retrospective studies. GH deficiency syndrome is associated with increased cardiovascular risk markers, and GH administration has been shown to have beneficial effects on a number of these factors. The aim of this 12-month study is to evaluate the effects of GH replacement on cardiovascular risk markers in women, ages 18-65, who are GH deficient due to pituitary/hypothalamic disease, radiation, or surgery. For the first 6 months of this study, subjects receive either GH or placebo (an inactive substance), and all subjects receive GH for the remaining 6 months of the study. We are assessing cardiovascular risk markers in the blood, body composition, flexibility of blood vessels, heart rate variability and quality of life.